v3.24.2.u1
REVENUES (Tables)
 6 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
Summary of Disaggregation of Revenues
The following table summarizes our Total revenues:
Three Months Ended June 30, 2024Three Months Ended June 30, 2023
(in millions)U.S.EuropeRest of WorldTotalU.S.EuropeRest of WorldTotal
Product sales:
HIV
Biktarvy$2,585 $370 $277 $3,232 $2,439 $302 $237 $2,979 
Descovy434 25 26 485 460 25 31 516 
Genvoya372 45 23 440 455 56 29 540 
Odefsey233 72 10 315 267 74 11 351 
Symtuza - Revenue share(1)
131 34 3 168 84 33 3 120 
Other HIV(2)
65 25 15 105 74 31 15 120 
Total HIV3,821 571 353 4,745 3,778 521 326 4,626 
Liver Disease
Sofosbuvir/Velpatasvir(3)
267 84 126 476 223 84 90 397 
Vemlidy117 11 115 243 96 10 113 219 
Other Liver Disease(4)
47 47 19 113 37 37 21 95 
Total Liver Disease431 142 259 832 356 131 225 711 
Veklury76 53 85 214 97 52 107 256 
Oncology
Cell Therapy
Tecartus63 37 7 107 56 29 4 88 
Yescarta186 169 58 414 217 133 30 380 
Total Cell Therapy250 206 66 521 272 162 34 469 
Trodelvy224 69 26 320 189 53 17 260 
Total Oncology474 275 92 841 462 215 51 728 
Other
AmBisome17 69 65 151 20 69 61 151 
Other(5)
98 8 24 130 64 10 17 92 
Total Other115 77 88 280 85 80 78 243 
Total product sales4,916 1,118 878 6,912 4,777 999 788 6,564 
Royalty, contract and other revenues25 15 1 41 6 28 1 35 
Total revenues$4,941 $1,133 $879 $6,954 $4,784 $1,027 $789 $6,599 
Six Months Ended June 30, 2024Six Months Ended June 30, 2023
(in millions)U.S.EuropeRest of WorldTotalU.S.EuropeRest of WorldTotal
Product sales:
HIV
Biktarvy$4,900 $735 $542 $6,177 $4,600 $606 $449 $5,656 
Descovy805 51 55 911 855 50 60 965 
Genvoya704 95 44 843 872 111 58 1,041 
Odefsey457 148 21 626 497 149 22 668 
Symtuza - Revenue share(1)
236 67 6 309 182 70 7 259 
Other HIV(2)
125 70 27 222 136 63 28 228 
Total HIV7,226 1,167 695 9,088 7,142 1,049 624 8,816 
Liver Disease
Sofosbuvir/Velpatasvir(3)
515 163 203 881 427 174 181 782 
Vemlidy212 22 233 467 183 19 216 418 
Other Liver Disease(4)
89 94 38 221 64 78 44 186 
Total Liver Disease816 279 474 1,569 674 271 441 1,386 
Veklury391 123 255 769 349 163 317 829 
Oncology
Cell Therapy
Tecartus118 73 16 207 114 56 6 177 
Yescarta357 327 110 794 427 254 58 739 
Total Cell Therapy475 400 126 1,001 542 310 65 916 
Trodelvy429 137 62 628 351 107 23 482 
Total Oncology904 537 188 1,629 893 417 88 1,398 
Other
AmBisome31 139 124 294 27 129 111 267 
Other(5)
156 18 36 209 127 22 26 175 
Total Other188 156 160 504 153 152 137 442 
Total product sales9,525 2,262 1,772 13,559 9,211 2,052 1,607 12,870 
Royalty, contract and other revenues49 30 2 81 25 54 3 81 
Total revenues$9,574 $2,292 $1,774 $13,640 $9,236 $2,106 $1,610 $12,951 
_______________________________
(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).
(2)    Includes Atripla, Complera/Eviplera, Emtriva, Sunlenca, Stribild, Truvada and Tybost.
(3)    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).
(4)    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Sovaldi, Viread and Vosevi.
(5)    Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig.
Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods
The following table summarizes revenues recognized from performance obligations satisfied in prior years:
Three Months EndedSix Months Ended
June 30,June 30,
(in millions)2024202320242023
Revenue share with Janssen and royalties for licenses of intellectual property$202 $158 $372 $350 
Changes in estimates$82 $77 $242 $237 
Summary of Contract Balances
The following table summarizes our contract balances:
(in millions)June 30, 2024December 31, 2023
Contract assets(1)
$165 $117 
Contract liabilities(2)
$76 $109 
________________________________
(1)    Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation.
(2)    Generally results from receipt of advance payment before our performance under the contract.